Minimal residual disease (MRD) negativity has emerged asone of the most powerful prognostic biomarkers in multi-ple myeloma (MM), consistently associated with prolongedprogression-free survival (PFS) and overall survival (OS). Theclinical significance of MRD negativity was first systematicallydemonstrated in a landmark meta-analysis of 21 studies (15 in-cluded in the quantitative analysis), comprising patients receiv-ing conventional chemotherapy, novel agents, and autologousstem cell transplantation (ASCT).
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction
D'Arrigo, Graziella;Tripepi, Giovanni;
2026
Abstract
Minimal residual disease (MRD) negativity has emerged asone of the most powerful prognostic biomarkers in multi-ple myeloma (MM), consistently associated with prolongedprogression-free survival (PFS) and overall survival (OS). Theclinical significance of MRD negativity was first systematicallydemonstrated in a landmark meta-analysis of 21 studies (15 in-cluded in the quantitative analysis), comprising patients receiv-ing conventional chemotherapy, novel agents, and autologousstem cell transplantation (ASCT).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Relapse Despite MRD.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
353.11 kB
Formato
Adobe PDF
|
353.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
